Martine Piccart is a highly distinguished Belgian medical oncologist renowned for her pivotal contributions to breast cancer research and treatment. Her work has significantly influenced global oncology practices, particularly through her leadership in designing and conducting large-scale international clinical trials.
Born in Belgium, Piccart completed her medical training and specialized in oncology, establishing her professional base at the Jules Bordet Institute in Brussels, a leading comprehensive cancer center. Throughout her tenure at the institute, she has held various significant positions, including Head of the Medicine Department.
Piccart's most far-reaching impact derives from her leadership roles in international collaborative research initiatives. She served as the President of the European Organisation for Research and Treatment of Cancer (EORTC) from 1997 to 2000, where she played a crucial role in advancing European cancer research strategies. In 1996, she co-founded the Breast International Group (BIG), an extensive network comprising academic breast cancer research groups from across the globe. As BIG's Chair and subsequent Co-Chair, Piccart has been instrumental in fostering unprecedented international collaboration, leading to the successful execution of numerous groundbreaking clinical trials involving thousands of patients and dramatically accelerating the development of new breast cancer treatments.
Her research interests encompass a broad spectrum of breast cancer aspects, including the development and evaluation of adjuvant and neoadjuvant therapies, the identification of prognostic and predictive biomarkers, and the implementation of precision medicine strategies. Her findings have directly informed and shaped international clinical practice guidelines, leading to improved outcomes and quality of life for countless breast cancer patients globally.
A dedicated advocate for patient-centered research, Piccart consistently emphasizes the critical role of international cooperation in overcoming research challenges and expediting the delivery of innovative therapies to patients. Her scientific achievements and exceptional leadership have been recognized with numerous prestigious awards and honors, including the ESMO Lifetime Achievement Award and the AACR Distinguished Public Service Award, reflecting her profound and lasting influence on the field of oncology.